A Phase 4 interventional study of onabotulinumtoxinA and bimatoprost ophthalmic solution 0.03% in Facial Rhytides, Crow's Feet Lines and Glabellar Lines, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-09.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE® (bimatoprost ophthalmic solution).
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
Biological: onabotulinumtoxinA · Drug: bimatoprost ophthalmic solution 0.03% · Device: JUVÉDERM® ULTRA XC · Device: JUVÉDERM® ULTRA PLUS XC · Device: JUVÉDERM® VOLUMA® XC
onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
Also known as: botulinum toxin Type A
bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
Also known as: LATISSE®
JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire
Participants assessed their satisfaction with the way they look right now with their entire face in mind using a 10-item questionnaire. Possible responses to each question were: 1=Very dissatisfied, 2=Somewhat dissatisfied, 3-=Somewhat satisfied and 4=Very satisfied. The responses were added across items and transformed to a Rasch scale ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in Aging Appearance Using a 7-item Questionnaire
Participants rated how they look now using a 7-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4=Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS)
Participants assessed how old they think they look compared to their actual age using a VAS by placing a mark on a number on a horizontal line where the far left of the line= -15 (look 15 years younger), 0=look current age, to the far right of the line=15 (look 15 years older). A positive change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in Social Confidence Using an 8-item Questionnaire
Participants assessed their social confidence with their facial appearance in mind in the past week using an 8-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in Psychological Well-Being Using a 10-item Questionnaire
Participants assessed their psychological well-being with their facial appearance in mind using a 10-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Participant's Self- Perception of Age (SPA)
Participants assessed SPA by answering the question: How do you think your facial appearance looks compared to your age today? Participants recorded how many years younger or older they thought their facial appearance made them look. A negative result indicates improvement (a younger appearance).
Time frame: Baseline, Month 4
Change From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS)
The investigator assessed the severity of the participant's GLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS
The investigator assessed the severity of the participant's CFLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in Investigator's Global Eyelash Assessment Score (GEAS)
The investigator assessed the participant's eyelash prominence using the 4-point GEAS where: 1=Minimal (worst), 2=Moderate, 3=Marked and 4=Very Marked (best). A positive change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS
The investigator assessed overall mid-face volume deficit using the Mid-face Volume Deficit Scale (MFVDS) where: 0=None (moon face; fullness) \[best\], 1=Minimal (flattening), 2=Mild (mild concavity), 3=Moderate (moderate concavity, 4=Significant (significant concavity) and 5=Severe (wasting) \[worst\]. A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity
The investigator assessed the participants nasolabial folds severity using the 5-Point Nasolabial Fold Severity (NLFS) Scale where: 0=None (no wrinkles) \[best\], 1=Mild (shallow, just perceptible wrinkle), 2=Moderate (moderately deep wrinkle), 3=Severe (deep wrinkle) or 4= Extreme (very deep wrinkle). A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity
The investigator assessed the participant's oral commissure using the 4-Point Oral Commissure Severity Scale (OCSS) where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity
The investigator assessed the participant's perioral lines severity using the 4-Point Perioral Lines at Rest Severity Scale (POLSS) where: 0=None (no lines) \[best\], 1=Mild (few, shallow lines), 2=Moderate (some moderate lines) or 3=Severe (many deep lines or crevices)\[worst\]. A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 4
Change From Baseline in the Participant Satisfaction With Appearance of Periorbital Area
Participants assessed how their overall eye appearance has affected them over the past 7 days using the 9-item Periorbital Aesthetic Appearance Questionnaire (PAAQ). Possible responses to each question were: 0=Never (best), 1=Rarely, 2=Some of the time, 3=Most of the time and 4=All of the time with a total possible score of 0 to 36. A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 4
| Milestone | All Participants |
|---|---|
| Started | 116 |
| Eligible and received treatment | 100 |
| Completed | 93 |
| Not completed | 23 |
| Withdrew: Screen failure | 14 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Personal reasons | 3 |
| Withdrew: Other miscellaneous reasons | 2 |
Participants assessed their satisfaction with the way they look right now with their entire face in mind using a 10-item questionnaire. Possible responses to each question were: 1=Very dissatisfied, 2=Somewhat dissatisfied, 3-=Somewhat satisfied and 4=Very satisfied. The responses were added across items and transformed to a Rasch scale ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 41.22 ± 11.97 |
| Change from Baseline at Month 4 | 31.70 ± 20.00 |
Participants rated how they look now using a 7-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4=Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 45.07 ± 18.85 |
| Change from Baseline at Month 4 | 28.47 ± 21.47 |
Participants assessed how old they think they look compared to their actual age using a VAS by placing a mark on a number on a horizontal line where the far left of the line= -15 (look 15 years younger), 0=look current age, to the far right of the line=15 (look 15 years older). A positive change from Baseline indicates improvement.
| years | All Participants |
|---|---|
| Baseline | 0.1 ± 4.28 |
| Change from Baseline at Month 4 (n=92) | -4.6 ± 4.36 |
Participants assessed their social confidence with their facial appearance in mind in the past week using an 8-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 62.70 ± 21.74 |
| Change from Baseline at Month 4 | 18.24 ± 23.04 |
Participants assessed their psychological well-being with their facial appearance in mind using a 10-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 62.78 ± 22.45 |
| Change from Baseline at Month 4 | 19.89 ± 20.63 |
Participants assessed SPA by answering the question: How do you think your facial appearance looks compared to your age today? Participants recorded how many years younger or older they thought their facial appearance made them look. A negative result indicates improvement (a younger appearance).
| years | All Participants |
|---|---|
| Baseline | 0.2 ± 4.08 |
| Month 4 | -4.6 ± 4.19 |
The investigator assessed the severity of the participant's GLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 2.6 ± 0.50 |
| Change from Baseline at Month 4 | -1.6 ± 0.78 |
The investigator assessed the severity of the participant's CFLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Left_Baseline | 2.5 ± 0.50 |
| Left_Change from Baseline at Month 4 | -1.0 ± 0.85 |
| Right_Baseline | 2.5 ± 0.50 |
| Right_Change from Baseline at Month 4 | -1.0 ± 0.85 |
The investigator assessed the participant's eyelash prominence using the 4-point GEAS where: 1=Minimal (worst), 2=Moderate, 3=Marked and 4=Very Marked (best). A positive change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 1.8 ± 0.42 |
| Change from Baseline at Month 4 | 1.5 ± 0.65 |
The investigator assessed overall mid-face volume deficit using the Mid-face Volume Deficit Scale (MFVDS) where: 0=None (moon face; fullness) \[best\], 1=Minimal (flattening), 2=Mild (mild concavity), 3=Moderate (moderate concavity, 4=Significant (significant concavity) and 5=Severe (wasting) \[worst\]. A negative change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 3.1 ± 0.36 |
| Change from Baseline at Month 4 | -1.7 ± 0.80 |
The investigator assessed the participants nasolabial folds severity using the 5-Point Nasolabial Fold Severity (NLFS) Scale where: 0=None (no wrinkles) \[best\], 1=Mild (shallow, just perceptible wrinkle), 2=Moderate (moderately deep wrinkle), 3=Severe (deep wrinkle) or 4= Extreme (very deep wrinkle). A negative change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 2.6 ± 0.51 |
| Change from Baseline at Month 4 | -1.0 ± 0.85 |
The investigator assessed the participant's oral commissure using the 4-Point Oral Commissure Severity Scale (OCSS) where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 2.1 ± 0.49 |
| Change from Baseline at Month 4 | -0.9 ± 0.67 |
The investigator assessed the participant's perioral lines severity using the 4-Point Perioral Lines at Rest Severity Scale (POLSS) where: 0=None (no lines) \[best\], 1=Mild (few, shallow lines), 2=Moderate (some moderate lines) or 3=Severe (many deep lines or crevices)\[worst\]. A negative change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 2.0 ± 0.57 |
| Change from Baseline at Month 4 | -1.1 ± 0.68 |
Participants assessed how their overall eye appearance has affected them over the past 7 days using the 9-item Periorbital Aesthetic Appearance Questionnaire (PAAQ). Possible responses to each question were: 0=Never (best), 1=Rarely, 2=Some of the time, 3=Most of the time and 4=All of the time with a total possible score of 0 to 36. A negative change from Baseline indicates improvement.
| score on a scale | All Participants |
|---|---|
| Baseline | 21.1 ± 6.71 |
| Change from Baseline at Month 4 | -12.6 ± 7.61 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | — | 0/100 (0%) | 18/100 (18%) |
| Event | All Participants |
|---|---|
| ContusionInjury, poisoning and procedural complications | 18/100 |
Safety population included all enrolled participants who received any study treatment.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 52.5 ± 7.40 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 96 |
| Male | 4 |
Ran from Jun 2014 to primary completion in May 2015, 10 months.
Results were first posted in Jun 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimatoprost Ophthalmic Solution